A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer.

Really pleased to announce the publication of our latest bit of research

https://doi.org/10.1111/bju.14811


We have developed a urine test to diagnose aggressive prostate cancer and predict whether patients will require treatment up to five years earlier than standard clinical methods. The experimental new test called ‘PUR’ (Prostate Urine Risk) also identifies men who are up to eight times less likely to need treatment within five years of diagnosis. It is hoped that the breakthrough could help large numbers of men avoid an unnecessary initial biopsy and repeated invasive follow-ups for ‘low risk’ patients on active surveillance.

This work was funded by the Movember Foundation, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, the Andy Ripley Memorial Fund and the Stephen Hargrave Trust.

We've had quite a bit of press attention:

Comments

Popular posts from this blog

Nationwide statement to QIF Format

Search down those house prices